TACC3 and intrahepatic cholangiocarcinoma: In contrast, FGFR2-TACC2 fusion without amplification has only been reported in a case of apocrine breast cancer [56], despite the fact that FGFR2 fusions with various partners, including FGFR2-TACC3, are relatively common in intrahepatic cholangiocarcinoma [27].